| Description | Ropidoxuridine (IPdR) is a novel, orally available halogenated thymidine analogue that holds promise as a sensitizer for human tumors.Ropidoxuridine is an orally available and bioavailable IUdR (5-iodo-2'-deoxyuridine) prodrug. |
| In vitro | Ropidoxuridine是IUdR的一种口服生物可用前药。在临床相关浓度下，Ropidoxuridine与Alisertib展现出明显的协同效应。[1] |
| In vivo | Ropidoxuridine (750 mg/kg/日) 与 Alisertib (30 mg/kg/日) 在正位肿瘤模型中展示了强烈的协同效应。[1] |
| Synonyms | IPdR |
| molecular weight | 338.1 |
| Molecular formula | C9H11IN2O4 |
| CAS | 93265-81-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 225.0 mg/mL (665.5 mM), Sonication is recommended. |
| References | 1. Rampurwala MM, et al. Ropidoxuridine (IPdR) potentiates alisertib (MLN8237) activity in triple-negative breast cancer. Cancer Res. 2016;76(4):6-13-16. 2. Saif MW, et al. IPdR: a novel oral radiosensitizer. Expert Opin Investig Drugs. 2007;16(9):1415-1424. 3. Kinsella TJ, et al. 5-iodo-2-pyrimidinone-2'-deoxyribose-mediated cytotoxicity and radiosensitization in U87 human glioblastoma xenografts. Int J Radiat Oncol Biol Phys. 2007;69(4):1254-1261. 4. Kummar S, et al. First-in-human phase 0 trial of oral 5-iodo-2-pyrimidinone-2'-deoxyribose in patients with advanced malignancies. Clin Cancer Res. 2013;19(7):1852-1857. |